Last updated: August 3, 2026
Claritin RediTabs is an orally disintegrating formulation of loratadine, a second-generation antihistamine originally commercialized by Schering-Plough. Its commercial peak occurred before and around the 2002 U.S. switch of Claritin from prescription to over-the-counter status. The product’s original pharmaceutical patents have expired, generic loratadine is widely available, and current competition is based mainly on retail distribution, brand recognition, price, dosage form and seasonal promotion.
Product-level revenue for Claritin RediTabs is not separately disclosed by current or former owners. Public financial reporting combines RediTabs with the broader Claritin brand or with consumer-health portfolios. The available evidence supports a trajectory from premium prescription product, to high-value OTC franchise, to mature branded OTC product with declining pricing power.
What is Claritin RediTabs and how does it differ from standard Claritin?
Claritin RediTabs contains loratadine and dissolves on the tongue without requiring water. It was developed for patients seeking a more convenient alternative to conventional tablets.
| Attribute |
Claritin RediTabs |
| Active ingredient |
Loratadine |
| Drug class |
Second-generation H1 antihistamine |
| Primary use |
Relief of seasonal allergic rhinitis and related allergy symptoms |
| Dosage form |
Orally disintegrating tablet |
| Original developer |
Schering-Plough |
| Current brand owner |
Bayer through its consumer-health business |
| Prescription status |
OTC in the United States |
| Biosimilar exposure |
None; loratadine is a small-molecule drug |
| Main competitors |
Generic loratadine, Claritin tablets, Claritin liqui-gels, Zyrtec, Allegra and store brands |
The RediTabs format was intended to create a convenience-based distinction within the loratadine franchise. That distinction supported premium pricing while the core loratadine molecule was protected. Once generic loratadine became widely available, the formulation’s commercial value depended more on consumer preference and brand loyalty than on molecule-level exclusivity.
When did Claritin lose prescription and patent exclusivity?
Claritin lost its central U.S. prescription-market protection in the early 2000s. The FDA approved loratadine as a prescription product in the 1990s and approved the OTC switch in 2002. The switch expanded distribution through mass retailers, pharmacies and supermarkets but also placed the brand in direct competition with low-cost generic loratadine.
The principal loratadine patent protection expired around the 2002 period, subject to patent-term and regulatory adjustments. FDA Orange Book records and historical patent data should be read at the NDA and patent level because the RediTabs formulation was not economically equivalent to the entire Claritin franchise. A formulation patent can protect a dosage form after the active ingredient patent expires, but it does not prevent generic manufacturers from selling conventional loratadine tablets or other permitted formulations.
Claritin exclusivity timeline
| Period |
Commercial and regulatory event |
| 1990s |
Loratadine marketed as a prescription antihistamine |
| Late 1990s |
RediTabs introduced as an orally disintegrating Claritin formulation |
| 2002 |
Claritin switched to OTC status in the United States |
| 2002 onward |
Generic loratadine competition expanded after core patent expiry |
| 2000s |
Claritin remained a major branded allergy franchise despite generic entry |
| 2010s |
Brand ownership moved through the Schering-Plough-Merck and Bayer transactions |
| 2020s |
Claritin operated as a mature OTC brand in a crowded antihistamine market |
The OTC switch increased addressable demand but accelerated the transition from prescription-style exclusivity to consumer-goods competition. That tradeoff was financially favorable during the initial switch period and less favorable once generic and store-brand products gained shelf space.
What patents protect Claritin RediTabs?
Claritin RediTabs historically relied on a layered protection strategy:
- Loratadine compound patents.
- Formulation and dosage-form patents.
- Product-specific regulatory exclusivity.
- Trademark protection for the Claritin and RediTabs names.
- Consumer recognition and retail placement.
The compound patent was the most commercially important right. Formulation patents could protect specific orally disintegrating compositions or manufacturing techniques, but they did not recreate the exclusivity of the original loratadine patent.
The current commercial barrier is trademark and brand equity, not patent exclusivity. Generic manufacturers can market loratadine products without using Claritin branding, subject to FDA requirements and applicable labeling rules. A generic manufacturer seeking to sell an orally disintegrating loratadine product may face formulation-specific patent issues that do not apply to standard tablets.
What formulations are protected by Claritin patents?
The RediTabs concept depends on a dosage form that disintegrates rapidly in the mouth. Relevant formulation issues can include:
- Disintegration time.
- Taste masking.
- Tablet strength and friability.
- Stability under humidity exposure.
- Packaging requirements.
- Manufacturing process controls.
- Excipients and compression technology.
Those characteristics can create technical or commercial barriers, but they are narrower than active-ingredient protection. Once the market contains multiple acceptable loratadine formulations, consumers and retailers can substitute across tablets, dissolving tablets, liquids and store-brand products.
What is the FDA and Orange Book status of Claritin RediTabs?
Claritin RediTabs originated as an FDA-approved drug product but now competes in the U.S. OTC market. The product’s economic position is governed primarily by the FDA’s OTC framework, approved labeling, manufacturing requirements and trademark rights.
The Orange Book remains relevant to historical NDA and patent analysis. It is less important to current commercial performance because:
- The central loratadine patent estate has expired.
- Loratadine is widely available as an approved generic.
- OTC products compete through retail and consumer channels.
- The RediTabs brand does not prevent substitution with generic loratadine.
- The product is not a biologic and has no biosimilar pathway.
FDA labeling identifies loratadine as a once-daily antihistamine used for allergy symptoms and hives. The FDA’s OTC Drug Facts labeling requirements standardize much of the consumer information across competing products, reducing the informational advantage of a branded product.
How did Claritin RediTabs affect the Claritin franchise’s revenue trajectory?
Claritin became one of Schering-Plough’s largest products before generic erosion. Public company filings reported Claritin at the brand or franchise level, not as a separate RediTabs revenue line. The brand reached multi-billion-dollar annual sales before patent expiration and the OTC transition, making it one of the most commercially significant allergy medicines of its period (Schering-Plough Corporation, 2001).
The financial trajectory can be divided into four stages.
Prescription growth
During the prescription period, Claritin benefited from once-daily dosing, low sedation relative to older antihistamines and broad physician adoption. Prescription reimbursement supported premium pricing, and the brand competed against other second-generation antihistamines such as cetirizine and fexofenadine.
OTC expansion
The 2002 OTC switch increased consumer access and allowed Claritin to reach mass-market retail channels. Advertising became a central growth mechanism. RediTabs contributed a convenience proposition that helped preserve brand segmentation within the OTC portfolio.
The switch also changed the revenue model. Prescription sales depended on physician prescribing and payer reimbursement. OTC sales depended on advertising, shelf position, retailer relationships and consumer willingness to pay.
Generic erosion
Generic loratadine reduced the price umbrella around the brand. Generic entry typically affects a mature small-molecule product through:
- Lower average selling prices.
- Retailer substitution.
- Private-label expansion.
- Reduced physician influence.
- Increased couponing and promotional spending.
- Pressure on premium formulations.
Claritin retained value because many consumers continued to purchase a familiar brand. That value was not equivalent to patent protection. It was a consumer franchise premium that weakened as retailers expanded store-brand offerings.
Mature OTC portfolio
After Schering-Plough merged with Merck in 2009, Claritin became part of Merck’s consumer-health portfolio. Bayer agreed to acquire Merck’s consumer-care business in 2014, bringing Claritin into Bayer’s consumer-health operations (Bayer AG, 2014).
Bayer’s public reporting has generally grouped Claritin within broader consumer-health or allergy categories. It has not provided a recurring, audited revenue series for RediTabs alone. The product should therefore be treated as a mature SKU within a larger brand rather than as a separately valued pharmaceutical asset.
How does Claritin RediTabs compare with Zyrtec and Allegra?
Claritin competes in the second-generation antihistamine category, where products are differentiated by perceived efficacy, onset, sedation profile, dosing convenience, price and brand familiarity.
| Factor |
Claritin RediTabs |
Zyrtec |
Allegra |
| Active ingredient |
Loratadine |
Cetirizine |
Fexofenadine |
| Dosage frequency |
Generally once daily |
Generally once daily |
Generally once or twice daily, depending on product |
| Primary differentiation |
Brand, non-water dosage form, loratadine familiarity |
Strong efficacy perception and rapid consumer adoption |
Non-drowsiness positioning and broad product range |
| Patent status |
Mature, expired small-molecule estate |
Mature OTC/generic market |
Mature OTC/generic market |
| Main substitution risk |
Generic loratadine and store brands |
Generic cetirizine and store brands |
Generic fexofenadine and store brands |
| Biosimilar risk |
None |
None |
None |
RediTabs competes less against prescription drugs than against other branded and private-label OTC allergy products. Its strongest direct threat is a cheaper loratadine product with comparable consumer utility. Its strongest category threats are Zyrtec and Allegra, especially when retailers use price promotions or when consumers perceive one active ingredient as more effective.
Which companies are challenging Claritin RediTabs?
The relevant challengers are generic drug manufacturers and private-label retailers rather than a single litigant. Major generic companies have marketed loratadine products in the United States, while retailers have sold store-brand loratadine under their own labels.
The competitive structure includes:
- Large generic manufacturers supplying national pharmacy chains.
- Retailer-controlled private labels.
- Branded OTC competitors such as Zyrtec and Allegra.
- Combination allergy and sinus products.
- Digital and mail-order pharmacies using lower-priced alternatives.
The absence of meaningful current patent exclusivity means market entry is not dependent on a single Paragraph IV event. Generic competition is already structural. Historical Paragraph IV filings may have affected the timing of generic launch, but current commercial risk is better measured through retail share, price gaps and shelf placement.
What generic entry risks exist for Claritin RediTabs?
Generic entry risk is high at the molecule level and moderate to high at the dosage-form level.
A generic conventional loratadine tablet can substitute for the active ingredient but may not replicate the RediTabs experience. A directly competing orally disintegrating product must address formulation performance, taste, stability and packaging. Even without direct RediTabs substitution, conventional generic loratadine exerts pricing pressure because many consumers do not require a dissolving tablet.
The principal risks are:
- Continued migration to low-price loratadine.
- Retailer substitution with private-label products.
- Reduced premium for branded Claritin.
- Promotional spending required to maintain awareness.
- Seasonal concentration in spring and summer allergy periods.
- Limited ability to raise prices without volume loss.
What patent litigation and settlements affected Claritin?
The major commercial litigation issue was historical generic entry against the loratadine franchise and related patents. The available public record supports analysis of the core loratadine patent and formulation protections through FDA patent listings, court records and company disclosures. Claritin RediTabs does not have a current litigation profile comparable to an active patented specialty drug or biologic.
No current biosimilar litigation applies. No ongoing exclusivity-based settlement should be assumed to protect the brand after the expiration of its principal patents. Any historical Paragraph IV settlement must be evaluated against the specific ANDA, patent number, dosage form and launch date rather than inferred from the Claritin brand name.
How strong is the current Claritin RediTabs patent estate?
The current patent estate is commercially weak because the relevant molecule-level rights have expired. The remaining defenses are primarily:
- Trademark protection.
- Trade dress and packaging.
- Formulation know-how.
- Manufacturing controls.
- Retail distribution.
- Consumer loyalty.
- Advertising scale.
Trademark protection can prevent competitors from using Claritin or RediTabs branding. It cannot stop sale of therapeutically equivalent loratadine products. Formulation know-how can improve product quality but does not create durable market exclusivity unless protected by enforceable, unexpired patents or regulatory restrictions.
What licensing deals and ownership changes involve Claritin?
Claritin’s ownership history is more important than licensing for current market analysis.
| Date |
Transaction or ownership event |
| Original commercialization |
Schering-Plough |
| 2009 |
Schering-Plough merged with Merck |
| 2014 |
Bayer agreed to acquire Merck’s consumer-care business |
| Current commercial position |
Bayer consumer-health portfolio |
The 2014 transaction transferred a broad group of consumer-health brands, including Claritin, rather than creating a product-specific licensing arrangement. Public disclosures do not establish a separately reported royalty stream for Claritin RediTabs.
What is the geographic coverage and manufacturing risk?
Claritin is a globally recognized brand, but product names, formulations and regulatory status vary by country. U.S. OTC status does not automatically determine the product’s classification in Europe, Canada, Asia or Latin America. Manufacturing and supply risks are typical of mature OTC products:
- Multiple approved manufacturing sites may reduce dependence on one facility.
- Orally disintegrating tablets can be more sensitive to humidity and packaging conditions.
- Seasonal demand can create inventory pressure.
- Retail promotions can cause short-term volume spikes.
- API sourcing and contract manufacturing affect margin and continuity.
Manufacturing know-how may support product quality, but it is not a substitute for active patent protection.
What is the outlook for Claritin RediTabs?
Claritin RediTabs is best classified as a mature, patent-expired OTC brand with a convenience-led product position. Revenue growth is unlikely to come from molecule exclusivity. The commercial outlook depends on brand investment, channel execution, seasonal allergy incidence, pricing discipline and the ability to preserve a premium over generic loratadine.
The product can remain profitable within a large consumer-health portfolio if marketing and distribution costs are controlled. Its strategic value is likely greater as part of the Claritin brand architecture than as an independently growing product. Financial exposure should be modeled using brand-level or allergy-category data, with RediTabs treated as a component rather than a standalone revenue stream.
Key Takeaways
- Claritin RediTabs is a loratadine orally disintegrating tablet marketed as an OTC allergy product.
- Its central small-molecule patent protection has expired.
- The 2002 OTC switch expanded access but shifted competition toward advertising, retail execution and price.
- Generic loratadine is the principal structural threat.
- RediTabs may retain a convenience premium, but that premium is not equivalent to patent exclusivity.
- Product-level revenue is not separately disclosed by Schering-Plough, Merck or Bayer.
- No biosimilar risk applies because loratadine is a small molecule.
- Current value rests on trademark, brand recognition, formulation know-how and distribution.
- Zyrtec, Allegra, generic loratadine and private-label products define the competitive set.
- The product is more appropriately valued as part of a mature OTC franchise than as a standalone pharmaceutical asset.
FAQs About Claritin RediTabs
Is Claritin RediTabs still patent protected?
The original loratadine patent protection has expired. Any remaining formulation or manufacturing rights must be assessed against specific patent claims and expiration dates.
Can generic loratadine replace Claritin RediTabs?
Yes. Generic loratadine can provide equivalent active-ingredient therapy, although it may not replicate the orally disintegrating format, taste or packaging.
Does Claritin RediTabs have biosimilar competition?
No. Biosimilars apply to biologic products. Loratadine is a small-molecule drug and competes with generic versions.
Why does Claritin RediTabs cost more than generic loratadine?
The price difference reflects branding, advertising, retail positioning, dosage-form convenience and consumer recognition rather than current molecule-level patent exclusivity.
Is Claritin RediTabs a separate revenue line for Bayer?
No separate RediTabs revenue figure is routinely disclosed in Bayer’s public financial reporting. Claritin is generally reported within broader consumer-health or allergy-related categories.
References
-
Bayer AG. (2014). Bayer to acquire Merck’s consumer care business. Bayer corporate press release.
-
Bayer AG. (2023). Annual report 2023. Bayer AG.
-
Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (n.d.). DailyMed: Loratadine drug labeling. U.S. National Library of Medicine.
-
Merck & Co., Inc. (2010). Annual report 2009. Merck & Co., Inc.
-
Schering-Plough Corporation. (2002). Annual report 2001. Schering-Plough Corporation.
-
U.S. Federal Trade Commission. (2002). FTC approves Schering-Plough’s switch of Claritin from prescription to over-the-counter status. Federal Trade Commission.
